Can't post a link, so this is all I could copy and paste from it.
About Isis Pharmaceuticals, Inc.
Isis Pharmaceuticals, Inc. (Isis) is engaged in antisense technology, exploiting a drug discovery platform to create
a pipeline of drugs. As of December 31, 2011, the Company operates in the Drug Discovery and Development
operations segments. The Drug Discovery and Development operations help the Company to identify drugs,
providing a wealth of potential targets to treat a range of diseases. As of December 31, 2011, the Company had
two generation 2.5 drugs in development, ISIS-STAT3Rx and ISIS-FVIIRx. During the year ended December
31, 2011, the Company had 26 drugs in development. Its partners are licensed to develop, with the Company’s
support, 10 of these 26 drugs. As of December 31, 2011, the Company owns 20% interests in Santaris Pharma
A/S, Achaogen Inc., and Atlantic Pharmaceuticals Limited, which are privately-held, and Antisense Therapeutics
Limitet (ATL), and iCo Therapeutics Inc., which are publicly utilities.
Highlights & Recent Developments
Isis is exploiting its leadership position in antisense technology to discover and
develop novel drugs for its product pipeline and for its partners. Isis’ broad
pipeline consists of 25 drugs to treat a wide variety of diseases with an emphasis
on cardiovascular, metabolic, severe and rare diseases, and cancer. Isis’ partner,
Genzyme, plans to commercialize Isis’ lead product, KYNAMRO, following regulatory
The company recently reported that it will receive $1.4 million from Alnylam
Pharmaceuticals, Inc. as its portion of the upfront fees in Alnylam’s recently announced
collaboration in the field of agriculture.
Revenue for the three and six months ended June 30, 2012 was $47.3 million and
$70.6 million, respectively, compared to $24.8 million and $46.0 million for the
same periods in 2011. The Company ended the second quarter of 2012 with $336
million in cash.